Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Diabetes AND Vildagliptin

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44366   clinical trials with a EudraCT protocol, of which   7389   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    66 result(s) found for: Diabetes AND Vildagliptin. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2012-001143-46 Sponsor Protocol Number: CLAF237ADE08 Start Date*: 2012-07-10
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A randomized open-label study to compare safety and efficacy of vildagliptin versus NPH insulin add-on to glimepiride in patients with type 2 diabetes mellitus that do not reach adequate glycemic c...
    Medical condition: type-2 diabetes mellitus that do not reach adequate glycemic control on their current sulfonylurea monotherapy
    Disease: Version SOC Term Classification Code Term Level
    15.0 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-016053-18 Sponsor Protocol Number: VILD1 Start Date*: 2009-12-09
    Sponsor Name:UMC St Radboud
    Full Title: The effect of vildagliptin on endothelium-dependent vasodilatation. A double blind, cross-over study in type 2 diabetes.
    Medical condition: The effect of vildagliptin on endothelial dysfunction in type 2 diabetes, assessed by measuring endothelium-dependent vasodilatation
    Disease: Version SOC Term Classification Code Term Level
    12.0 10048554 Endothelial dysfunction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002230-37 Sponsor Protocol Number: CLAF237ANL05T Start Date*: 2013-12-19
    Sponsor Name:Erasmus Medical Center
    Full Title: “Novel Approach to Detect the Detailed Effects of Vildagliptin on Beta-cell Dynamics in Patients with Early-onset Type 2 Diabetes”
    Medical condition: impaired fasting glucose/impaired glucose tolerance, prediabetes
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004722-16 Sponsor Protocol Number: CLAF237B2224 Start Date*: 2009-03-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as add-on therapy to metformin in patients with type 2 diabetes
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    9.1 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) EE (Completed) IT (Completed) FI (Completed) SK (Completed) DE (Completed) AT (Completed) LT (Completed) SE (Completed) LV (Completed) BE (Completed) DK (Completed) GR (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004412-12 Sponsor Protocol Number: CLAF237B2201 Start Date*: 2009-02-27
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind study to evaluate the efficacy and long-term safety of vildagliptin modified release (MR) as monotherapy in patients with type 2 diabetes
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2006-002794-51 Sponsor Protocol Number: CLMF237A2302 including amd 2 Start Date*: 2006-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, active-controlled, multicentre study to compare the effect of 24 weeks treatment with a fixed combination therapy of vildagliptin and metformin to the individual monothe...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) IT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-021097-11 Sponsor Protocol Number: CLAF237A23152 Start Date*: 2010-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind placebo controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin 50 mg bid as add-on therapy to metformin plus glimepiri...
    Medical condition: Type II Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-010967-18 Sponsor Protocol Number: DM-UMCU-01 Start Date*: 2009-11-11
    Sponsor Name:University Medical Centre Utrecht
    Full Title: Effect of adding vildagliptin to start of insulin treatment in combination with metformin in patients with type 2 diabetes
    Medical condition: patients with type 2 diabetes, failing on maximal oral glucose-lowering drugs, starting on insulin therapy in combination with standard metfromin (2 x 850)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022658-18 Sponsor Protocol Number: CLAF237A23150 Start Date*: 2011-04-11
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of 24 weeks treatment with vildagliptin in type 2 diabetes mellitus patients ≥ 70 years (drug-...
    Medical condition: Type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    12.1 10067585 Type 2 diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) SK (Completed) DE (Completed) BG (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-003712-23 Sponsor Protocol Number: CLAF237A23156 Start Date*: 2012-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 5-year study to compare the durability of glycemic control of a combination regimen with vildagliptin & metformin versus standard-of-care monotherapy with metformin, initiated in treatment-naive...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) FI (Completed) LV (Completed) IT (Completed) HU (Completed) DE (Completed) EE (Completed) SK (Completed) BG (Completed) PL (Completed) NO (Completed) CZ (Completed) AT (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003723-21 Sponsor Protocol Number: CLAF237A23137 Start Date*: 2007-11-22
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, randomized, double-blind clinical trial to evaluate the safety and tolerability of 24 weeks treatment with vildagliptin (50 mg qd) versus placebo in patients with type 2 diabetes an...
    Medical condition: Diabetes Type 2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) FR (Completed) ES (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2011-000518-21 Sponsor Protocol Number: CLMF237ADE02 Start Date*: 2011-06-20
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Cross-over study to assess the difference in fasting plasma glucose (FPG) between vildagliptin (Galvus®/Eucreas®) and sitagliptin (Januvia®/Janumet®) after two weeks (FPG-VISIT)
    Medical condition: Diabetes mellitus type 2
    Disease: Version SOC Term Classification Code Term Level
    13.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2006-002466-19 Sponsor Protocol Number: CLAF237A2398 Start Date*: 2006-09-06
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Randomized, Double-Blind, Active Controlled Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd or Metformin 1500 mg daily in Elderly Drug Naïve Patients wi...
    Medical condition: Type II Diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10045242 Type II diabetes mellitus LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) ES (Completed) AT (Completed) EE (Completed) IT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2011-006118-15 Sponsor Protocol Number: CLAF237ADE07 Start Date*: 2012-06-13
    Sponsor Name:Novartis Pharma GmbH
    Full Title: Multicentric cross-over trial to assess the glycemic profiles on 8 weeks of vildagliptin and sitagliptin treatment, each, in type-2 diabetic patients with a pre-existing cardiovascular disease pre-...
    Medical condition: type-2 diabetes mellitus with pre-existing cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000538-37 Sponsor Protocol Number: CLAF237ADE02 Start Date*: 2007-06-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A multicenter, randomized, double-blind, parallel-group study to investigate the glucose lowering effect, safety and tolerability of a 24 week treatment with Vildagliptin 100 mg o.a.d. versus place...
    Medical condition: Type II diabetes mellitus inadequate control
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-002778-30 Sponsor Protocol Number: CLAF237A2357 Start Date*: 2005-10-19
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Assess the Efficacy and Safety of 12 Week Treatment with Vildagliptin (LAF237) 50 mg QD in Subjects with Impaire...
    Medical condition: Type II Diabetes
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) FI (Completed) SE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2015-001334-21 Sponsor Protocol Number: 350A Start Date*: 2015-08-31
    Sponsor Name:Lund University
    Full Title: Study of the Effect of Vildagliptin versus Dapagliflozin on Glucagon Response to Mixed Meal in Metformin-treated Subjects with Type 2 Diabetes
    Medical condition: Type 2 Diabetes Mellitus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020684-20 Sponsor Protocol Number: CLAF237A23135 Start Date*: 2010-09-29
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24-week, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50mg bid as an add-on therapy to insulin, with or witho...
    Medical condition: Type II Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.0 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed) DE (Completed) GB (Completed) BE (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2006-001138-42 Sponsor Protocol Number: CLAF237A23103 Start Date*: 2006-08-31
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment with Vildagliptin 100 mg qd to Placebo as Add-On Therapy in Patients with Type 2 Diabetes I...
    Medical condition: Type 2 Diabetes
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063624 Type II diabetes mellitus inadequate control LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2012-005399-32 Sponsor Protocol Number: DPP-IVEPC Start Date*: 2013-01-22
    Sponsor Name:AZIENDA OSPEDALIERA DI PARMA
    Full Title: Randomized, open label, two parallel arms, intervention trial comparing the effect of DPP-IV inhibitor Vildagliptin vs. Glibenclamide on circulating EPCs.
    Medical condition: type 2 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004861 10012614 Diabetes mellitus NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jan 14 04:11:48 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA